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Teaser Systemic diseases where foci are initially unrelated to the GI tract do in fact alter GI
physiology and function. This ultimately affects the bioavailability of orally administered
drugs.
Gut reaction: impact of systemic
diseases on gastrointestinal
physiology and drug absorption
Grace B. Hattonz, Christine M. Madlaz, Sarit C. Rabbie and
Abdul W. Basit
UCL School of Pharmacy, University College London, 29–39 Brunswick Square, London, WC1N 1AX, UK
It was in 400 BC that Hippocrates reportedly stated that ‘‘death sits in the
colon”. The growth in our knowledge of the intestinal microbiome and the
gut–brain axis, their function and imbalance, has distinctly uncovered the
complex relationship between the gut to disease predisposition and
development, heralding the problem and the solution to disease
pathology. Human studies of new drug molecules are typically performed
in healthy volunteers and their specific disease indication. Approved
drugs, however, are used by patients with diverse disease backgrounds.
Here, we review the current literature of the gastrointestinal tract reacting
to systemic disease pathology that elicits physiological and functional
changes that consequently affect oral drug product performance.
Introduction
Oral drug absorption in the gastrointestinal (GI) tract is a complex process with numerous factors
contributing to low and erratic drug absorption. Such parameters include GI transit time,
motility, pH, luminal contents and composition, permeation and transport systems, and the
interactions between host and microbiome [1–7]. Interindividual differences in GI physiology are
expected to acutely affect drug behaviour; however, some factors that might cause drug variabili-
ty on one occasion might not elicit profound effects on another. This is further complicated when
the GI environment is not only perturbed by GI diseases but also negatively ‘reacts’ to the
potential impact of systemic diseases of various aetiologies that can concomitantly affect the GI
tract and, thus, oral drug absorption.
Over 2000 years ago, the father of modern medicine, Hippocrates ascribed that ‘‘death begins
in the colon”. Although this is a case of oversimplification, Hippocrates forecasted the relation-
ship between poor gut-health and the development of disease. The drug development process is
required to optimise drug bioavailability for maximum therapeutic effect; however, the potential
influence of disease is often neglected in the picture. Attempts have been made to elucidate the
influence of GI diseases including irritable bowel syndrome, inflammatory bowel diseases (IBD),
malabsorptive syndromes, microbial dysbiosis, GI infections and the impact of GI surgery on GI
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IEWhysiology, function and, consequently, dosage form perfor-
ance [8,9]. The impact of systemic disease, however, is scarcely
ppreciated.
Systemic disease can be defined as a disorder that affects the
ody in its entirety and, thus, is not limited to a single organ or
ody part. Although we speculate that a larger portfolio of sys-
emic diseases can affect the GI tract and oral drug absorption,
onsequently limited data in the literature are available that
vestigate the complex relationship between disease–drug inter-
ctions. However, systemic diseases stemming from genetic muta-
ions, neurodegenerative in origin, autoimmune and metabolic
alfunction, infectious disease and nervous system injury includ-
g cystic fibrosis, Parkinson’s disease, diabetes, human immuno-
eficiency virus (HIV) and pain were selected for review owing to
vailable data in the literature. These disorders were chosen herein
o raise awareness that diseases with no immediate association to
he GI environment can, however, clinically manifest GI altera-
ions with respect to physiology and function and, thus, influence
rmulation behaviour. In addition, whereas patients will take
edicines specifically for the aforementioned diseases, little is
nderstood on the outcome of drug bioavailability in patients
ith multiple and diverse disease backgrounds. This review, there-
re, addresses the implications of the altered GI tract as a conse-
uence of systemic disease and its impact on oral drug
ioavailability.
ystic fibrosis
ystic fibrosis (CF) is a prominent example of a hereditary, severe,
rogressive and multisystemic disorder with varying worldwide
revalence. In North America, the frequency of CF is 1 in every
500 individuals; but in Asia 1 in 100 000–350 000 individuals are
ffected. Prevalence of CF in Africa and South America are steadily
creasing to 1 case in every 8000 people; however, studies have
hown its regional dependence with the southern regions of both
ontinents demonstrating an increasing incidence of CF [10]. CF
volves the mutation of the cystic fibrosis transmembrane con-
uctance regulator (CFTR) gene which affects the movement of
alt and water in and out of cells. People diagnosed with CF
xperience a build-up of thick sticky mucus in the lungs and
he digestive system, manifesting symptoms at multiple bodily
ites. The most common of these are the respiratory tract and
istinctive – and often detrimental – changes to GI physiology and
nction; the latter is characterised by gastro–oesophageal reflux
isease, malabsorption and pancreatic insufficiency [11]. Fat and
utrient malabsorption in CF patients is also common and is
rther affected by altered intestinal pH, motility and mucosal
bnormalities [12].
In terms of drug pharmacokinetics, increased plasma and renal
learance of dicloxacillin [13], as well as its increased volume of
istribution and decreased half-life [14], have been reported in CF
atients when compared with healthy subjects (Fig. 1). This is
imilarly true for cephalopsorins which have been shown to
emonstrate higher total bodily clearance in CF [15]. Intestinal
ransit changes in CF patients are incompletely understood al-
hough factors such as mucosal inflammation [16] and small
testinal bacterial overgrowth (SIBO) [17] have been identified
reported. For instance, oral–colon transit time (OCTT) has been
shown to be unchanged in terms of the migrating motor complex
[18] or prolonged following the administration of a single-unit
dosage form [19,20] at different regions of the GI tract in fasted CF
patients, potentially contributing to wide variability in oral drug
absorption and bioavailability. A study by Collins et al. demon-
strated that gastric emptying (GE) is up to 30% faster in fed-state
CF patients (average 53.0 min) when compared with healthy
subjects (average 72.2 min), although marked discrepancies in
gastric emptying time (GET) have also been observed including
58 min (range 6–107 min) and 41 min (range 4–125 min) noted
within the same study [21].
In the small intestine, transit is significantly delayed in CF
which is thought to be a consequence of abnormal intestinal
mucous blocking normal transit. A study by Bali et al. [19] exam-
ined the small intestinal transit times (SITT) of ten CF patients
(seven males and three females between 17 and 24 years of age)
against 15 control subjects (nine males and six females between 18
and 26 years of age). SITT in CF patients ranged from 160 to
390 min, whereas the control group demonstrated a regular SITT
of 50–150 min. However, it has also been observed that, whereas
SITT is delayed in CF patients, duodenal and jejunal transit can
also be abnormally fast in some subjects until the point of pH
neutralisation in the intestine and activation of the ‘ileal brake’
[22].
In terms of pH, dysfunction of CFTR has been associated with
reductions in pancreatic and duodenal – but not gastric – bicar-
bonate secretions [23], thereby lowering pre- and post-prandial
duodenal pH by 1–2 units when compared with healthy controls
(pH 5–7 versus pH 6, respectively). Low duodenal pH specifically in
CF has been cited as the combined result of gastric hyperacidity
and reduced pancreatic bicarbonate secretions [24]. Indeed, the
efficacy of enteric-coated pancreatic enzyme preparations
designed to dissolve above pH 5 for this purpose has been brought
into question. Discrepancies in ranges observed for gastric pH have
been noted according to different sources in fasted subjects with
Youngberg et al. [25] citing between pH 0.9 and pH 1.8 in subjects
with use of the Heidelberg Capsule and pH 1.3 according to
Barraclough and Taylor [24]. However, sharp changes in pH from
the terminal ileum (7.5) to the caecum (6.4) in CF patients when
compared with the gradual increase in pH along the same length in
healthy controls have been observed and, thus, could be responsi-
ble for aberrations in the delivery of pH-sensitive formulations
[22].
A further study identified reduced oral drug bioavailability in CF
patients following lung transplantation owing to impaired GI
absorption. The absorption of tacrolimus, a highly lipophilic
immunosuppressive drug often administered following allogeneic
organ transplant to lower the risk of organ rejection, was studied in
11 subjects following lung grafts and 11 CF individuals after lung
transplants. Knoop et al. identified that tacrolimus pharmacoki-
netics were highly variable in CF patients and non-CF individuals
[26]. This is due to the AUC of tacrolimus in non-CF recipients of
lung grafts being 35 ng-h/ml/mg when compared with 17.3 ng-
h/ml/mg for the 11 CF transplant recipients. The oral clearance of
tacrolimus in the CF population, therefore, was 50% owing to
EVIEWS Drug Discovery Today Volume 00, Number 00 December 2018s contributing factors in animal models. Moreover, the inconsis-
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ciency, which can severely hamper fat absorption [27]. It is conse-n gastrointestinal physiology and drug absorption, Drug Discov Today (2018), https://doi.org/
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FIGURE 1
Mean cloxacillin serum concentrations following 25 mg/kg oral administration in 12 healthy subjects () and 12 cystic fibrosis patients (*). Reproduced, with
permission, from Ref. [14].quently often advised that tacrolimus should be delivered through
an alternative drug delivery route to ensure effective therapeutic
outcome for CF patients.
The intestinal microbiome of those with CF was found to be
significantly less diverse when compared with non-CF controls. In
particular, the relative abundance of Bacteroidetes was decreased
whereas significant increases in Firmicutes were demonstrated in
CF patients. Disease severity also contributed to microbial dysbio-
sis and individuals with severe lung dysfunction demonstrate a
significantly reduced a diversity when compared with those with
mild or moderate pulmonary impairment [28]. The slower SITT in
CF patients can further lead to SIBO, characterised by the excessive
concentrations of bacteria in the proximal small intestine. SIBO
would be expected to enhance the translocation of intestinal
bacterial products and harbour microbial-associated molecular
patterns that are capable of stimulating Toll-like receptors, thus
triggering inflammation and fibrogenic pathways [29]. It is sug-
gested that, owing to SIBO, the synthesis of enterotoxic and
unabsorbable metabolites could result in mucosal damage and
interfere with digestion and absorption. In addition, the type of
microbial flora present contributes to the manifestation of signs
and symptoms or overgrowth. For example, a predominance of
bacteria that metabolise bile salts to unconjugated or insoluble
compounds could lead to fat malabsorption or bile acid diarrhoea
[30]. The administration of the antibiotic ciprofloxacin, however,
was shown to improve the digestion and absorption of fat CF
patients with SIBO [30].
Parkinson’s disease
Parkinson’s disease (PD) is the second-most-common progressive
and irreversible neurodegenerative disease with evolving layers of
complexity. Its pathology involves extensive regions of the ner-Please cite this article in press as: Hatton, G.B. et al. Gut reaction: impact of systemic diseases on 
10.1016/j.drudis.2018.11.009vous system, an array of neurotransmitters and protein aggregates;
but it is mainly characterised by the loss of dopaminergic neurons
in the substantia nigra. The cause of PD remains unknown; how-
ever, is seems to result from a complicated interplay of genetic and
environmental factors affecting fundamental cellular processes.
Cardinal symptoms of PD include bradykinesia, tremor, restless-
ness and postural instability. In many cases, motor symptoms of
PD are preceded by a series of milder prodromal symptoms such as
fatigue and GI symptoms including constipation, dysphagia and
defecatory dysfunction [31]. Epidemiological studies show that PD
is predominant in mid-aged or older adults with a higher preva-
lence in males (61 cases in every 100 000) compared with females
(38 cases in every 100 000) [32].
The appearance of early GI symptoms could also indicate that
part of the pathological process originates in the gut given the
abundance of enteric dopaminergic neurons collectively using
50% of bodily dopamine [33], although GI symptoms are other-
wise typically evident at all stages of PD. The gut–brain axis
appears to dominate in PD because symptoms ranging from ab-
dominal bloating, dyspepsia, nausea, vomiting and pain can be
exacerbated by emotion [34]. Constipation is otherwise the most
common GI symptom in PD reported by 90% of patients and
with the majority of cases associated with advanced disease pro-
gression [35].
Jost and Schimrigk [36] suggested that, in addition to impaired
colonic motility, reduced tension of abdominal muscles and the
diaphragm could contribute to the prolonged colon transit time in
PD. Davies et al. administered oral mannitol to 15 PD patients as
part of a study investigating intestinal permeability; in normal
subjects, monosaccharides such as mannitol are absorbed by non-
mediated diffusion through small channels in the enterocyte
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IEWre absorbed across tight junctions or between enterocytes. In PD,
he percentage of mannitol absorption was reduced to 11.7%
hen compared with the healthy control group achieving
6.2% urinal mannitol recovery [37]. This suggested a reduction
 the absorptive surface area of the small intestine owing to
pecific alterations in the enterocyte brush-border membrane in
D patients.
Abnormal GET has been described in 43–83% of PD patients [38]
nd is currently the most investigated parameter in relation to GI
ymptoms. Most antiparkinsonian drugs are delivered orally;
herefore, altered gastric motility and GE rate might affect the
ioavailability of medications and the rate of absorption from the
I tract is fundamental in achieving a beneficial therapeutic effect.
 a study by Edwards et al. [39], 28 untreated patients with PD
ere assessed and found to have an average time to empty half of
he gastric contents (GET1/2) of 59 min when compared with
4 min in a group of slightly younger healthy control individuals.
n interesting association has also been made between delayed
ET and the response fluctuations that develop after long-term
vodopa therapy. Studies measuring gastric retention after 1 h
howed GET to be increased but GET1/2 significantly delayed in
atients with fluctuations when compared with those without
uctuations. This demonstrates that GET is more significant in
hose PD patients displaying response fluctuations [40]. Another
ossible outcome of GET is the prolonged exposure of drugs to
astric acid and digestive enzymes, as well as the binding of food
omponents such as proteins in the stomach. In this instance,
opa-decarboxylase normally present in the gastric mucosa would
e unable to metabolise protein-bound levodopa to the active
opamine, leading to absence of any therapeutic effect.
The short half-life of levodopa, its erratic absorption from the
roximal part of the small intestine, the minimal absorption from
he stomach, its peripheral metabolism and competition with
rge neutral amino acids from the intestinal barrier are crucial
ctors that can all hinder the cerebral availability of levodopa.
atients 1–3 (Fig. 2) demonstrate the unpredictable treatment and
uctuations to drug responses but experience a fourfold increase in
ean Tmax following duodenal absorption when compared with
ral administration [41]. This, therefore, suggests a delayed and
complete absorption caused by slower GE of levodopa in PD
atients.Please cite this article in press as: Hatton, G.B. et al. Gut reaction: impact of systemic diseases o
10.1016/j.drudis.2018.11.009
Patient 1 P












7 8 9 10 11 12 13 7 8 9
IGURE 2
evodopa plasma concentrations after () oral administration and (*) duoden
eproduced, with permission, from Ref. [41].
 www.drugdiscoverytoday.comGastroparesis, the reduced motility of the stomach, can be
present in early and advanced PD. Few attempts have been
achieved to overcome gastroparesis in PD patients by either adjust-
ing dietary requirements when administrating drugs or with the
use of prokinetic agents such as cisapride, domperidone and
metoclopramide to normalise GE [42]. Different formulation
approaches have also been employed to prolong drug transit in
the upper GI tract to maximise the opportunity for absorption. For
example, in one study, the difference between solid and liquid
emptying time in PD patients was exploited as a method of
optimising drug delivery with results showing that dispersible
or liquid formulations of levodopa can, in fact, decrease Q3Tmax
[43]. However, levodopa absorption takes place primarily in the
intestine and not the colon, rendering targeting difficult. In
addition, it appears that these formulations are still dependent
on erratic GET, to which end Nyholm [44] suggested administering
a levodopa gel solution directly into the duodenum or jejunum.
This gel-formulation approach was shown to achieve consistent
plasma levodopa levels in treated patients with the effective
management of motor complications.
Most PD patients will present comorbidities and will often be
prescribed cardiovascular and respiratory agents. Algeri et al. ob-
served that the co-administration of the anticholinergic drug
trihexyphenidyl reduced peak plasma levels of levodopa when
compared with levodopa alone (from 2.29  0.36 mg/ml to
1.90  0.49 mg/ml). Trihexyphenidyl further decreased maxi-
mum peak levels and the AUC of levodopa (Fig. 3) as a conse-
quence of increased gastric metabolism of the drug from delayed
GE in PD patients. When levodopa was administered parentally,
total levodopa plasma concentrations and half-life were not mod-
ified by the presence of trihexyphenidyl. The combined parkinso-
nian therapy to anticholinergic agents, therefore, can result in
decreased bioavailability [45].
Emerging evidence has revealed the presence of an intense
dialogue between the brain and the GI system, hence the term:
gut–brain axis. It is becoming appreciated that a third player that is
the intestinal microbiome can influence the bidirectional crosstalk
between the gut and brain regarding the pathogenesis of PD. GI
manifestations appear 20 years before motor impairments; how-
ever, it is still unclear which condition comes first and what role
the gut and the gut microbiome have on the progression of PD.n gastrointestinal physiology and drug absorption, Drug Discov Today (2018), https://doi.org/










7 8 9 10 11 12 1310 11 12 13
Drug Discovery Today 
al delivery of a single dose of levodopa in Parkinson’s disease subjects.
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FIGURE 3













WBacteria more commonly associated with anti-inflammatory prop-
erties such as butyrate-producing bacteria including Blautia and
Coprococcus were significantly lower in PD patients when com-
pared with healthy individuals, whereas an increase in abundance
of the genus Ralstonia was found in the mucosa of PD patients [46].
Like CF patients, a significant proportion of PD patients demon-
strate SIBO or the colonisation of Helicobacter pylori [47] where the
eradication of these result in improvements of GI manifestations
and motor fluctuations. In particular, the antibiotic treatment for
H. pylori has been shown to improve levodopa absorption and
bioavailability [48].
Diabetes
There are two manifestations of diabetes mellitus (DM) including
type 1 DM (T1DM) and type 2 DM (T2DM). T1DM is an autoim-
mune disorder caused by the immune-mediated destruction of
insulin-producing pancreatic b cells with a multifactorial interplay
between genetic, environmental and immune factors. This results
in the inability of the pancreas to create insulin, which conse-
quently increases glucose levels in the bloodstream. Hyperglycae-
mia in T2DM, however, results from absolute or relative insulin
deficiency which is attributed to the inability to compensate for
insulin resistance. Similar to T1DM, the aetiology of insulin resis-
tance in T2DM is theorised to be a combination of genetic and
metabolic factors, although central obesity notably contributes to
T2DM development. Both DM manifestations, however, feature
significant links to impaired GI tract function [49]. The incidence
of DM has at least quadrupled in the past three decades and is thePlease cite this article in press as: Hatton, G.B. et al. Gut reaction: impact of systemic diseases on 
10.1016/j.drudis.2018.11.009ninth major cause of death. Epidemiology studies have shown that
approximately one in 11 adults worldwide are diagnosed with DM
with 90% of those being T2DM individuals. Asia is a major area of
the rapidly emerging DM global epidemic, with China and India
being the top two epicentres. Although genetic predisposition
partly contributes to individual susceptibility, an unhealthy diet
and sedentary lifestyle are important drivers for the prevalence of
T2DM specifically [50].
There is ample evidence to suggest that diabetes and the GI tract
are inextricably linked. The interaction between the upper GI tract
and the endocrine system is important in the regulation of me-
tabolism; the GI tract has a heterogenous cellular content and
comprises a variety of cells that influence paracrine and endocrine
mediators that collectively form the entero-endocrine system [51].
Some studies have shown that pronounced hyperglycaemia
(>250 mg/dl) affects the motility of the oesophagus, stomach,
small intestine and colon in T1DM and T2DM individuals [52].
Diabetes is further believed to affect the morphology and function
of the GI tract (Table 1), which can consequently influence oral
drug performance [53]. An inverse relationship has also been
demonstrated whereupon alterations to the GI environment
and particularly intestinal permeability, including immune
responses and gut microbiota composition, have been seen to
affect diabetes pathogenesis [54].
Diabetic patients exhibit significantly reduced gastric acid se-
cretion [55], which is more pronounced in diabetic gastroparesis
[56]. Furthermore, gastric pH is also increased in the fasted state of
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TABLE 1
Diabetes-mellitus-inducedQ12 physiological, motor and sensory changes in the small intestine and colona
Changes Small intestine Colon
Mucosa  Increased thickness
 Damaged tight junctions
 Decreased membrane fluidity
 Enhanced transport of glucose, amino acids, bile
salts, phosphate, fatty acids, fatty alcohols and
cholesterol
 Decreased protein synthesis
 Increased expression of monosaccharide
transporters
 Increased thickness
 Increased thickness of subepithelial collagen layer
 Increased expression of AGE and RAGE
Submucosa  Increased thickness  Increased thickness
 Increased expression of AGE and RAGE
Wall  Increased thickness
 Increase expression of AGE and RAGE
 Increased thickness
Motor  Highly variable transit time
 Decreased muscle tone
 Increased jejunal and ileal contractility in response
to distension
 Dysmotility
 Increased transit time
 Highly variable contractility
 Highly variable spontaneous contractility
 Impaired contraction and relaxation of circular muscle strips
Sensory  Decreased duodenal sensitivity in response to
mechanical, thermal and electrical stimulations
 Increased jejunal sensitivity in response to
mechanical stimulation
 Increased colonic sensitivity to mechanical stimulation
Abbreviations: AGE, advanced glycation end-product; RAGE, advanced glycation of end-product receptor.











IEWg to impaired absorption of basic drugs in the stomach [57].
hanges in aboral pH can also impair the disintegration and
issolution of coated dosage forms, particularly those incorporat-
g pH-sensitive materials. Indeed, modern enteric coatings such
s cellulose acetate phthalate, polyvinylacetate phthalate and the
olymethacrylates are almost entirely insoluble at normal gastric
H but begin to dissolve rapidly above pH 5 [58]. Equally, diabetes
as also been shown to delay GET [59] and total GI transit time
0], whereas diabetes-associated diarrhoea can also have clinical
plications for drugs such as antiretrovirals that have not been
eadily absorbed before they are excreted [61].
A study investigated the pharmacokinetic activity of atorvasta-
in acid and its main metabolites in human liver microsomal
actions from nondiabetic and diabetic donors [62]. In diabetic
atients, it was identified that the average dose-normalised con-
entrations of atorvastatin lactone and its o- and p-OH metabolites
ere significantly higher during the absorption phase (Fig. 4).
ecause atorvastatin lactone formation takes place at low pH
vels, the prolonged gastric transit time observed in diabetic
atients can promote the oral bioavailability of atorvastatin lac-
one in the GI tract. The altered drug response, therefore, should
e taken into consideration when initiating atorvastatin acid
reatment in patients with diabetes.
In addition, one of the major microvascular complications of
M includes a 60–70% reduction of gastric mucosal blood flow,
hich ultimately influences the rate of GE. It has been reported
hat 28–65% of diabetic patients experience delayed GE which
auses a 300% longer gastric transit time in diabetic patients when
ompared with healthy subjects [63]. The significant changes in
astric motility and gastric transit time, therefore, can impact the
xtent of absorption in orally administered drugs. For example,
wer serum concentrations of oral ampicillin were demonstratedPlease cite this article in press as: Hatton, G.B. et al. Gut reaction: impact of systemic diseases o
10.1016/j.drudis.2018.11.009
 www.drugdiscoverytoday.comin DM patients when compared with healthy controls despite
unaltered elimination kinetics [64]. With regards to the microbial
environment in diabetes, T1DM and T2DM diabetes subjects
display key differences in gut dysbiosis. The imbalance of microbes
related to mucosal barrier function is altered in diseases where
Lactobacilli, Bifidobacteria and Roseburia are depleted, whereas
Clostridium perfringerns, Bacteroides and Prevotella are enriched
[65]. In T1DM, there is also a decrease in the number of Firmicutes
in favour of Bacteroidetes; whereas in T2DM Firmicutes levels are
elevated, contributing to the development of chronic inflamma-
tion and, in turn, obesity and insulin resistance [66]. In addition,
evidence has indicated that metformin induces rapid changes in
gut bacterial composition [67,68] that, although possibly improv-
ing glucose homeostasis, could have negative implications on the
pharmacokinetics of concomitantly administered drugs such as
organic cation transporter (OCT)-1 inhibitors [69] cimetidine and
verapamil. Other factors such as the significant reduction in
cytochrome (CYP)3A4 enzyme levels in DM have considerable
potential to alter the bioavailability of CYP3A4 drug substrates
such as atorvastatin, carbamazepine and budesonide [70].
HIV infection
HIV infection and AIDS is chronic and, to all intents and purposes,
irreversible. HIV specifically attacks cluster T cells which aid the
immune system to overcome infections. If HIV is untreated, HIV
reduces the number of T cells in the body, which increases the
likelihood of contracting other infections. The number of people
living with HIV and AIDS has been steadily increasing and reached
a total of 38.8 million in 2015. Mortality rates, however, have
declined from 1.8 million deaths in 2005 to 1.2 million deaths a
decade later. Sub-Saharan Africa demonstrates the highest concen-
tration of HIV-infected individuals with 1.8 million people beingn gastrointestinal physiology and drug absorption, Drug Discov Today (2018), https://doi.org/










































Drug Discovery Today 
FIGURE 4
The dose-normalised concentration of atorvastatin acid (ATV), ortho-hydroxy atorvastatin acid (o-OH-ATV), para-hydroxy atorvastatin acid (p-OH-ATV),
atorvastatin-lactone (ATV-LAC), ortho-hydroxy atorvastatin lactone (o-OH-ATV-LAC) and para-hydroxy atorvastatin lactone (p-OH-ATV-LAC) in the absorption













Wdiagnosed annually. Outside of sub-Saharan Africa, Southeast Asia
accounted for 4.7% of global infections in 2015 with equal preva-
lence in both sexes. The highest estimated incidence rate in Europe
was recorded in Russia with 607 000 people diagnosed [71].
In vitro studies have postulated that there is a reduction in the
number of enterocytes differentiating in HIV/AIDS patients, ulti-
mately leading to morphological changes in the intestinal lining
and compromising intestinal epithelial barrier function [72], thus
not only predisposing to opportunistic infections and more-ex-
tensive cellular damage but also impairing the absorption of orally
delivered drugs. Gastric hypochlorhydria and hypoacidity have
also been observed in AIDS patients up to a pH value 1.5–3-times
higher than that of healthy individuals [73], which can lead to
reduction in the absorption and subsequent bioavailability of basic
drugs such as ketoconazole [74] and itraconazole [75]. An altered
gastric pH owing to HIV/AIDS infection can also feature self-
implicating knock-on effects; for example, the drugs indinavir
and delavirdine used in infection treatment have been shown
to be <50% absorbed at alkaline pH values [76]. Equally, up to
20% of patients with AIDS feature abnormal intestinal permeabil-
ity [77]. As disease progresses, the functional and selective absorp-
tive surface area of the intestine decreases, as evidenced by a study
of mannitol permeability in HIV/AIDS patients with and without
diarrhoea [78]. These changes can concomitantly influence the
oral therapeutic efficacy of drugs for infections such as tuberculo-
sis, which is seen to be the most common opportunistic infection
in HIV/AIDS patients worldwide. For instance, Gurumurthy et al.
[79] demonstrated that peak concentrations for rifampicin and
isoniazid were reduced in HIV patients which followed an earlier
study that revealed that rifampicin and ethambutol plasma con-
centrations were significantly low in HIV/AIDS patients [80].
Reduced drug bioavailability could also be caused by fat malab-
sorption syndromes prevalent in the majority of HIV patients [81].Please cite this article in press as: Hatton, G.B. et al. Gut reaction: impact of systemic diseases on 
10.1016/j.drudis.2018.11.009Hyperlipidemia can have significant implications, therefore, on
the pharmacokinetics of lipid-soluble drugs such as the antiretro-
viral drug zidovudine. Zidovudine pharmacokinetics were highly
altered when administered to HIV-infected patients; Cmax was
reduced to 6.39  3.39 mmol/l versus 11.51  5.01 mmol/l and
Tmax was prolonged to 0.81  0.51 h versus 0.40  0.14 h in
HIV-infected patients when compared with healthy subjects
(Fig. 5). These data suggest a delayed absorption rather than an
altered metabolism of zodivudine in AIDS-related small intestinal
defect as a result of fat malabsorption [82]. Prominent fat malab-
sorption is further linked to the reduced bioavailability of rifam-
picin in the treatment of opportunistic tuberculosis in HIV-
infected patients; rifampicin plasma concentrations were reduced
by 32% in HIV patients when compared with the control owing to
GI malabsorption. GI malfunction can further increase rifampicin
clearance by reducing its reabsorption in the enterohepatic circu-
lation which can explain why rifampicin is associated with a large
decrease in total and peak exposure in HIV patients [83]. In
addition to its reduced bioavailability, rifampicin can also nega-
tively affect the absorption of the antiretroviral medication efavir-
enz. If co-administration is necessary for efavirenz and rifampicin,
HIV patients would require an increased dose of 800 mg from
600 mg daily because AUC is reduced by 26% in the presence of the
antibiotic (Fig. 5) [84].
A reduced microbial diversity has also been reported for HIV-
infected patients. Specifically, a shift to Bacteroides and Prevotella
predominance with a significant reduction in the Firmucutes
phyla, when compared to uninfected individuals, contributes to
a loss in immune regulatory and probiotic activity [85]. The effect
of HIV on the gut mucosal barrier might be a direct result from
microbial dysbiosis, which could induce a leak in gut mucosa and,
thus, trigger systemic inflammation from the circulation of mi-
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FIGURE 5
Comparison of zidovudine and zidovudine glucuronide plasma concentration (mmol/l) versus time (h) profiles following the oral administration of zidovudine in
patients with normal fat absorption when compared with impaired fat absorption in the HIV-infected group. –*– denotes zidovudine in AIDS patients with
impaired fat absorption; . . . * . . . denotes zidovudine in AIDS patients with normal fat absorption; –– denotes glucuronide zidovudine in AIDS patients with












IEWsed to control the rapid replication rate of HIV in plasma [87]. For
xample, BILR355, a non-nucleotide reverse transcriptase inhibi-
or, is co-administered with ritonavir. The drug combination acts
o interfere with the reproductive cycle of HIV and boosts BILR 355
fficacy by inhibiting its metabolism by CYP3A4-mediated catab-
lism [88]. A metabolite of BILR 355, however, is unusually in-
reased to toxic levels when the drug is concomitantly
dministered. It is now recognised that ritonavir triggers BILR
44 metabolism which is reduced to an intermediate by the gut
icrobiota in patients with HIV, followed by further oxidation to
he metabolite BILR 516 which exceeds the concentration of the
dministered drug [89]. This demonstrates how the gut micro-
iome can induce the biotransformation of drugs to create an
lternative metabolic pathway that could result in adverse effects
0].
ain
ain is a phenomenon separate from nociception in that it refers to
igher conscious perception of an unpleasant feeling, rather than
he process of neuronal transmission of noxious stimuli. The
lobal burden of chronic pain is projected to be large and growing
 parallel to noncommunicable disease burden with chronic pain
ffecting at least 20% of the European population with a higher
revalence in women, the same being true in the geriatric popula-
ion [91]. Heightened pain perception can occur as a result of a
ombination of central and peripheral sensitisation. The hypotha-
mic-pituitary-adrenal axis is activated by stress, which results in
he secretion of corticotropin-releasing hormone into the hypo-Please cite this article in press as: Hatton, G.B. et al. Gut reaction: impact of systemic diseases o
10.1016/j.drudis.2018.11.009
 www.drugdiscoverytoday.comphyseal portal system. This activates the anterior pituitary and
subsequent release of adrenocorticotropic hormone (ACTH) into
the systemic circulation. In response to ACTH, the adrenal cortex
releases cortisol, which can directly activate resident immune cells
and extrinsic primary afferents within the GI tract to promote
peripheral sensitisation [92]. GI physiology can consequently be
altered by pain owing to the gut–brain axis in terms of motility,
visceral perception, secretion, intestinal permeability, reduced
regenerative capacity of GI mucosa and mucosal blood flow and
negative effects on the intestinal microbiome [93]. For example, in
paediatric studies, correlating episodes of functional abdominal
pain with GE revealed an inverse relationship where higher pain
scores were demonstrated in subjects with low GE and antral
motility [94]. In this study, 13 out of 31 patients featured delayed
GE where the mean abdominal pain score was significantly higher
(P < 0.05) than for those with normal GE. Sixteen out of 31 also
featured abnormal gastric myoelectrical activity.
Jamali and Kunz-Dober [95] identified that the absorption of
orally administered analgesics can be impaired following dental
surgery. Plasma concentrations of ibuprofen were measured before
and after the removal of wisdom teeth in 14 patients. A marked
decrease in the AUC (0–2 h) was observed post-surgery in 13
patients, along with inhibition of the chiral inversion of the serum
ibuprofen enantiomer concentrations, which delay the onset of
analgesia. The exact mechanisms responsible for this observation
were not fully understood, although postoperative fatigue was
proposed as one that can temporarily reduce nutritional intake
and therefore delay Tmax [96]; stress-induced decreases in GE andn gastrointestinal physiology and drug absorption, Drug Discov Today (2018), https://doi.org/















Wblood flow to the GI tract [97] potentially contribute to reduced
drug absorption and GI motility by the depression of the vagus
nerve. This indicates that higher drug doses are required to achieve
the same analgesic effect as pre-surgery in patients suffering from
pain.
It is common that chronic pain patients such as those diag-
nosed with rheumatoid arthritis (RA) can present co-morbidities.
Because chronic pain is capable of altering the healthy GI envi-
ronment, the oral administration of drugs prescribed for other
disease indications can be compromised, such as the case of
verapamil for the treatment of high blood pressure, angina
and supraventricular tachycardia. Inflammation increases plasma
concentrations of a1-acid glycoprotein (AAG), potentially lead-
ing to a reduction in drug clearance where much of the drug
remains bound to these glycoproteins. Mayo et al. [98] showed
that RA causes a significant rise in the serum concentration of R-
verapamil (AUC of 125  34 mg/ml/min) and S-verapamil (AUC
of 33.6  6.8 mg/ml/min) enantiomers when compared with the
controls (AUC 39.1  4.6 mg/ml/min for R-verapamil; 8.1 
1.2 mg/ml/min for S-verapamil) (Fig. 6). However, this did not
otherwise increase patient response but instead decreased verap-
amil activity, probably because of the increase in drug–protein
binding. This suggests that, unlike in conditions dominated by
pain symptoms that can necessitate an increase in drug dosing to
achieve therapeutic concentrations, the reverse is necessary in
inflammatory conditions to limit excessive rises in AUC. Howev-
er, this will also depend on whether an increase in AUC correlates
with an increase in the unbound form of the drug, which might
not be strictly harmful to the patient. The situation inevitably
becomes more complicated, however, when both conditions are
present such as in IBD flare-ups.
Microbial dysbiosis has also been associated with several types
of pain including visceral, inflammatory, autoimmune-related
pain and migraine [46]. SIBO and H. pylori are associated with
abdominal pain and damage the gastric and intestinal mucosa
through bacterial adherence and toxin production. Similar to what
























Serum verapamil enantiomer concentration–time profiles in healthy control subj
administration of 80 mg verapamil. Reproduced, with permission, from Ref. [98].travel via the humoral or vagal afferent pathways to interact with
systemic mechanisms to induce pain [99]. A study by Pimentel
et al. demonstrated that 78% of patients suffering with fibromyal-
gia were also diagnosed with SIBO [100]. The administration of
antibiotic therapy was successful in bacterial eradication, which
reported improvement in GI symptoms including diarrhoea,
bloating, constipation and joint pain.
Concluding remarks
Changes in the GI environment as a result of GI diseases and their
impact on drug absorption have been superficially acknowledged;
however, even less is known about the consequences of diseases
indirectly linked to the GI tract. We report that the healthy GI
environment with regards to gastric and small intestinal transit
times, pH, intestinal permeability and microbial composition
negatively reacts to the prevalence of CF, PD, diabetes, HIV and
pain, which, in turn, collectively alter oral dosage form perfor-
mance. This, however, is only the ‘tip of the iceberg’ in terms of
fully elucidating the effect of systemic diseases. We envisage that a
nonexhaustive portfolio of systemic indications has the potential
to present GI manifestations and alter oral drug pharmacokinetics
and pharmacodynamics. Much like drug–drug interactions being
assessed during drug development, to optimise drug therapy, we
therefore encourage further research in the direction of drug–
disease interactions. The development of suitable in vitro dissolu-
tion models and in silico models for patients with diseases can
contribute to improve overall drug therapy because patients can
present co-morbidities and diverse disease backgrounds. This
would advance the identification of potential differences in ab-
sorption between healthy and different diseased states and, thus,
accelerate the translation of important new drugs to patients.
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